BeOne Medicines (ONC) Reports $1.5B Revenue for Q4, $1.1B from Lymphoma Treatment

BeOne Medicines AG (NASDAQ:ONC) is among the

.

On February 26, BeOne Medicines AG (NASDAQ:ONC) reported total global revenues of $1.5 billion for the fourth quarter of 2025 and $5.3 billion for 2026, increases of 33% and 40% from the prior-quarter and prior-year periods, respectively. Brukinsa, the company’s lymphoma and leukemia treatment, had revenues of $1.1 billion and $3.9 billion for the fourth quarter and full year, respectively, up 38% and 49% from the prior periods.

After the earnings report, on February 27, Truist Securities raised its price target on BeOne Medicines AG (NASDAQ:ONC) to $412 from $400 while maintaining a Buy rating on the stock. Truist adjusted its price target after incorporating the quarterly results, fiscal 2026 guidance, and insights from post-earnings discussions with the company.

Truist Securities noted BeOne Medicines AG (NASDAQ:ONC)’s fiscal 2026 revenue guidance of $6.2 billion to $6.4 billion roughly brackets consensus estimates of $6.4 billion and has led to added pressure on the shares. The analyst said that its current outlook on BeOne Medicines AG (NASDAQ:ONC) suggests healthy growth for Brukinsa even without any major label expansion.

Grail Inc.'s Galleri cancer test screening kit. Photo from Grail website

BeOne Medicines AG (NASDAQ:ONC) is a global oncology company that discovers and develops innovative treatments that are more affordable and accessible to cancer patients worldwide.

While we acknowledge the potential of ONC as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the

.